Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-ą„¦.ą„Øą„§%
ą„§,ą„¦ą„Æą„§.ą„«ą„§
-ą„Ø.ą„©ą„¦
-ą„¦.ą„Øą„§%
ā€”ą„§,ą„¦ą„Æą„©.ą„®ą„§ą„§,ą„¦ą„Æą„¬.ą„«ą„Øą„§,ą„§ą„¦ą„¦.ą„Øą„Øą„§,ą„¦ą„Æą„§.ą„«ą„§ā€”ā€”
SIXC
Communications
SIXC
Communications
SIXC
+ą„¦.ą„Øą„Ø%
ą„¬ą„§ą„¦.ą„§ą„§
+ą„§.ą„©ą„Ŗ
+ą„¦.ą„Øą„Ø%
ā€”ą„¬ą„¦ą„®.ą„­ą„­ą„¬ą„¦ą„®.ą„­ą„­ą„¬ą„§ą„Ø.ą„Æą„­ą„¬ą„¦ą„®.ą„­ą„­ā€”ā€”
SIXE
Energy
SIXE
Energy
SIXE
-ą„§.ą„©ą„Ŗ%
ą„§,ą„Øą„©ą„­.ą„Æą„®
-ą„§ą„¬.ą„®ą„©
-ą„§.ą„©ą„Ŗ%
ā€”ą„§,ą„Øą„«ą„Ŗ.ą„®ą„§ą„§,ą„Øą„«ą„©.ą„¦ą„§ą„§,ą„Øą„«ą„©.ą„®ą„­ą„§,ą„Øą„Øą„¬.ą„©ą„©ā€”ā€”
SIXI
Industrials
SIXI
Industrials
SIXI
-ą„¦.ą„Æą„©%
ą„§,ą„­ą„Ŗą„Ŗ.ą„­ą„§
-ą„§ą„¬.ą„Ŗą„¦
-ą„¦.ą„Æą„©%
ā€”ą„§,ą„­ą„¬ą„§.ą„§ą„§ą„§,ą„­ą„¬ą„Ŗ.ą„Øą„­ą„§,ą„­ą„¬ą„¬.ą„®ą„®ą„§,ą„­ą„Ŗą„Ŗ.ą„­ą„§ā€”ā€”
SIXM
Financials
SIXM
Financials
SIXM
-ą„¦.ą„©ą„­%
ą„¬ą„Ŗą„¦.ą„§ą„®
-ą„Ø.ą„Ŗą„¦
-ą„¦.ą„©ą„­%
ā€”ą„¬ą„Ŗą„Ø.ą„«ą„®ą„¬ą„Ŗą„Ŗ.ą„®ą„­ą„¬ą„Ŗą„®.ą„Ŗą„®ą„¬ą„Ŗą„¦.ą„§ą„®ā€”ā€”
SIXR
Staples
SIXR
Staples
SIXR
-ą„¦.ą„§ą„®%
ą„®ą„Ŗą„Æ.ą„«ą„®
-ą„§.ą„«ą„«
-ą„¦.ą„§ą„®%
ā€”ą„®ą„«ą„§.ą„§ą„©ą„®ą„«ą„«.ą„¬ą„¬ą„®ą„«ą„®.ą„­ą„«ą„®ą„Ŗą„«.ą„«ą„¬ā€”ā€”
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-ą„¦.ą„Øą„©%
ą„Øą„§ą„­.ą„Ŗą„®
-ą„¦.ą„«ą„¦
-ą„¦.ą„Øą„©%
ā€”ą„Øą„§ą„­.ą„Æą„®ą„Øą„§ą„­.ą„Æą„®ą„Øą„§ą„®.ą„¬ą„«ą„Øą„§ą„¬.ą„®ą„®ā€”ā€”
SIXT
Technology
SIXT
Technology
SIXT
+ą„§.ą„«ą„Ø%
ą„©,ą„Øą„¬ą„¦.ą„¬ą„Æ
+ą„Ŗą„®.ą„®ą„¬
+ą„§.ą„«ą„Ø%
ā€”ą„©,ą„Øą„§ą„§.ą„®ą„©ą„©,ą„Øą„Øą„­.ą„Øą„§ą„©,ą„Øą„¬ą„®.ą„©ą„®ą„©,ą„Øą„Øą„¬.ą„«ą„«ā€”ā€”
SIXU
Utilities
SIXU
Utilities
SIXU
-ą„¦.ą„¬ą„Æ%
ą„Æą„Ŗą„Ø.ą„Ŗą„«
-ą„¬.ą„«ą„©
-ą„¦.ą„¬ą„Æ%
ā€”ą„Æą„Ŗą„®.ą„Æą„®ą„Æą„Ŗą„®.ą„«ą„®ą„Æą„«ą„­.ą„®ą„©ą„Æą„Ŗą„§.ą„Æą„­ā€”ā€”
SIXV
Health care
SIXV
Health care
SIXV
-ą„¦.ą„«ą„Ø%
ą„§,ą„Ŗą„¬ą„¬.ą„®ą„¦
-ą„­.ą„­ą„Ø
-ą„¦.ą„«ą„Ø%
ā€”ą„§,ą„Ŗą„­ą„Ŗ.ą„«ą„Øą„§,ą„Ŗą„­ą„Æ.ą„¦ą„©ą„§,ą„Ŗą„®ą„§.ą„¦ą„Ŗą„§,ą„Ŗą„¬ą„¬.ą„®ą„¦ā€”ā€”
SIXY
Discretionary
SIXY
Discretionary
SIXY
+ą„¦.ą„Øą„Ø%
ą„Ø,ą„©ą„Æą„­.ą„«ą„¦
+ą„«.ą„©ą„®
+ą„¦.ą„Øą„Ø%
ā€”ą„Ø,ą„©ą„Æą„Ø.ą„§ą„Øą„Ø,ą„©ą„Æą„¬.ą„Æą„«ą„Ø,ą„Ŗą„Øą„§.ą„Øą„Øą„Ø,ą„©ą„®ą„Ø.ą„©ą„Øā€”ā€”
Q1 2026 earnings ā€¢ released ā€¢ EPS beat +ą„§ą„§.ą„§ą„Ŗ% ā€¢ Revenue beat +ą„«.ą„Øą„Ŗ%
See results
BMY:NYSE
Bristol-Myers Squibb Co
US$Ā ą„«ą„®.ą„Øą„Ø
-ą„©.ą„Æą„§%
(-ą„Ø.ą„©ą„­) 1D
US$Ā ą„«ą„®.ą„«ą„¦
+ą„¦.ą„Ŗą„®% (+ą„¦.ą„Øą„®)
After hours
Closed: ą¤®ą„‡ ą„§, ą„§ą„¬:ą„¦ą„¦:ą„¦ą„Ŗ GMT-ą„Ŗ  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMY...
Open
US$Ā ą„¬ą„¦.ą„¦ą„Ø
High
US$Ā ą„¬ą„¦.ą„¦ą„®
Low
US$Ā ą„«ą„®.ą„¦ą„©
Mkt. cap
ą„§.ą„§ą„ÆĀ ą¤–ą¤°ą¤¬
Volume
ą„§.ą„®ą„ŖĀ ą¤•ą¤°ą„‹ą¤”
Dividend
ą„Ŗ.ą„©ą„©%
Quarterly dividend
US$Ā ą„¦.ą„¬ą„©
Ex dividend date
ą„Øą„¦ą„Øą„¬ ą¤œą¤Øą¤µą¤°ą„€ ą„Ø
P/E ratio
ą„§ą„¬.ą„©ą„Ŗ
52-wk high
US$Ā ą„¬ą„Ø.ą„®ą„Æ
52-wk low
US$Ā ą„Ŗą„Ø.ą„«ą„Ø
EPS
US$Ā ą„©.ą„«ą„¬
Beta
ą„¦.ą„Øą„­
Shares outstanding
ą„Ø.ą„¦ą„ŖĀ ą¤…ą¤°ą¤¬
No. of employees
ą„©ą„ØĀ ą¤¹ą¤œą¤¾ą¤°
News stories
From sources across the web
Simply Wall Street
Simply Wall Street
·
ą„Ø ą¤˜ą¤£ą„ą¤Ÿą¤¾ ą¤Ŗą¤¹ą¤æą¤²ą„‡
A Look At Bristol Myers Squibb (BMY) Valuation After Its Q1 2026 Earnings Beat And Reaffirmed Guidance
MarketBeat
MarketBeat
·
ą„Ŗ ą¤˜ą¤£ą„ą¤Ÿą¤¾ ą¤Ŗą¤¹ą¤æą¤²ą„‡
Mcdonald Partners LLC Grows Holdings in Bristol Myers Squibb Company $BMY
Yahoo Finance
Yahoo Finance
·
ą„§ą„® ą¤˜ą¤£ą„ą¤Ÿą¤¾ ą¤Ŗą¤¹ą¤æą¤²ą„‡
BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts
Seeking Alpha
Seeking Alpha
·
ą„§ ą¤¦ą¤æą¤Ø ą¤Ŗą¤¹ą¤æą¤²ą„‡
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY)
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employeesą„©ą„Ø.ą„«Ā ą¤¹ą¤œą¤¾ą¤°
Foundedą„§ą„®ą„®ą„­
Headquartersą¤Øą„ą¤Æą„‚ ą¤Æą„‹ą¤°ą„ą¤• ą¤¶ą¤¹ą¤°, ą¤Øą„ą¤Æą„‚ ą¤Æą„‹ą¤°ą„ą¤•, ą¤øą¤‚ą¤Æą„ą¤•ą„ą¤¤ ą¤°ą¤¾ą¤œą„ą¤Æ ą¤…ą¤®ą„‡ą¤°ą¤æą¤•ą¤¾
Sector-
Websitebms.com
Last report
ą„Øą„¦ą„Øą„¬ ą¤…ą¤Ŗą„ą¤°ą¤æą¤² ą„©ą„¦
Fiscal Period
Q1 2026
Normalized EPS / Estimate
ą„§.ą„«ą„®/ (ą„§.ą„Ŗą„Ø est.)USD
+ą„§ą„§.ą„§ą„Ŗ%beat
Revenue / Estimate
ą„§ą„§.ą„Ŗą„ÆĀ ą¤…ą¤°ą¤¬/ (ą„§ą„¦.ą„Æą„ØĀ ą¤…ą¤°ą¤¬ est.)USD
+ą„«.ą„Øą„Ŗ%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ą„Øą„¦ą„Øą„« ą¤œą„ą¤Ø
ą„Øą„¦ą„Øą„« ą¤øą„‡ą¤Ŗą„ą¤Ÿą„‡ą¤®ą„ą¤¬ą¤°
ą„Øą„¦ą„Øą„« ą¤”ą¤æą¤øą„‡ą¤®ą„ą¤¬ą¤°
ą„Øą„¦ą„Øą„¬ ą¤®ą¤¾ą¤°ą„ą¤š
Revenue
ą„§ą„Ø.ą„Øą„­Ā ą¤…ą¤°ą¤¬
ą„§ą„Ø.ą„Øą„ØĀ ą¤…ą¤°ą¤¬
ą„§ą„Ø.ą„«ą„¦Ā ą¤…ą¤°ą¤¬
ą„§ą„§.ą„Ŗą„ÆĀ ą¤…ą¤°ą¤¬
Cost of goods sold
ą„©.ą„©ą„¬Ā ą¤…ą¤°ą¤¬
ą„©.ą„©ą„§Ā ą¤…ą¤°ą¤¬
ą„©.ą„«ą„§Ā ą¤…ą¤°ą¤¬
ą„©.ą„Ŗą„ØĀ ą¤…ą¤°ą¤¬
Cost of revenue
ą„©.ą„©ą„¬Ā ą¤…ą¤°ą¤¬
ą„©.ą„©ą„§Ā ą¤…ą¤°ą¤¬
ą„©.ą„«ą„§Ā ą¤…ą¤°ą¤¬
ą„©.ą„Ŗą„ØĀ ą¤…ą¤°ą¤¬
Research and development expenses
ą„Ø.ą„Øą„¬Ā ą¤…ą¤°ą¤¬
ą„Ø.ą„Ŗą„©Ā ą¤…ą¤°ą¤¬
ą„Ø.ą„«ą„¬Ā ą¤…ą¤°ą¤¬
ą„Ø.ą„¬ą„«Ā ą¤…ą¤°ą¤¬
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
ą„§.ą„¬ą„ÆĀ ą¤…ą¤°ą¤¬
ą„§.ą„­ą„ÆĀ ą¤…ą¤°ą¤¬
ą„Ø.ą„¦ą„ÆĀ ą¤…ą¤°ą¤¬
ą„§.ą„¬ą„ØĀ ą¤…ą¤°ą¤¬
Operating expense
ą„Ŗ.ą„­ą„®Ā ą¤…ą¤°ą¤¬
ą„«.ą„¦ą„«Ā ą¤…ą¤°ą¤¬
ą„«.ą„Ŗą„­Ā ą¤…ą¤°ą¤¬
ą„Ŗ.ą„­ą„¦Ā ą¤…ą¤°ą¤¬
Total operating expenses
ą„®.ą„§ą„ŖĀ ą¤…ą¤°ą¤¬
ą„®.ą„©ą„¬Ā ą¤…ą¤°ą¤¬
ą„®.ą„Æą„®Ā ą¤…ą¤°ą¤¬
ą„®.ą„§ą„ØĀ ą¤…ą¤°ą¤¬
Operating income
ą„Ŗ.ą„§ą„©Ā ą¤…ą¤°ą¤¬
ą„©.ą„®ą„¬Ā ą¤…ą¤°ą¤¬
ą„©.ą„«ą„ØĀ ą¤…ą¤°ą¤¬
ą„©.ą„©ą„¬Ā ą¤…ą¤°ą¤¬
Other non operating income
ą„©ą„Æ.ą„Æą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„«ą„Ø.ą„Æą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„«ą„Ŗ.ą„Ŗą„¦Ā ą¤•ą¤°ą„‹ą¤”
-ą„©.ą„Øą„¦Ā ą¤•ą¤°ą„‹ą¤”
EBT including unusual items
ą„§.ą„­ą„­Ā ą¤…ą¤°ą¤¬
ą„©.ą„§ą„§Ā ą¤…ą¤°ą¤¬
ą„§.ą„Ŗą„­Ā ą¤…ą¤°ą¤¬
ą„©.ą„Øą„ŖĀ ą¤…ą¤°ą¤¬
EBT excluding unusual items
ą„Ŗ.ą„Øą„ØĀ ą¤…ą¤°ą¤¬
ą„Ŗ.ą„¦ą„­Ā ą¤…ą¤°ą¤¬
ą„©.ą„®ą„¬Ā ą¤…ą¤°ą¤¬
ą„©.ą„©ą„©Ā ą¤…ą¤°ą¤¬
Income tax expense
ą„Ŗą„¬.ą„¦ą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„Æą„§.ą„Æą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„©ą„®.ą„Ŗą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„«ą„¬.ą„§ą„¦Ā ą¤•ą¤°ą„‹ą¤”
Effective tax rate
ą„Øą„«.ą„Æą„¬%
ą„Øą„Æ.ą„«ą„§%
ą„Øą„¬.ą„§ą„Ø%
ą„§ą„­.ą„©ą„Ø%
Other operating expenses
-
-
-
-
Net income
ą„§.ą„©ą„§Ā ą¤…ą¤°ą¤¬
ą„Ø.ą„Øą„¦Ā ą¤…ą¤°ą¤¬
ą„§.ą„¦ą„ÆĀ ą¤…ą¤°ą¤¬
ą„Ø.ą„¬ą„®Ā ą¤…ą¤°ą¤¬
Net profit margin
ą„§ą„¦.ą„¬ą„®%
ą„§ą„®.ą„¦ą„§%
ą„®.ą„¬ą„Æ%
ą„Øą„©.ą„©ą„¦%
Earnings per share
ą„§.ą„Ŗą„¬
ą„§.ą„¬ą„©
ą„§.ą„Øą„¬
ą„§.ą„«ą„®
Interest and investment income
ą„§ą„©.ą„Æą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„§ą„¬.ą„§ą„¦Ā ą¤•ą¤°ą„‹ą¤”
ą„§ą„Ŗ.ą„®ą„¦Ā ą¤•ą¤°ą„‹ą¤”
-
Interest expense
-ą„Ŗą„®.ą„«ą„¦Ā ą¤•ą¤°ą„‹ą¤”
-ą„Ŗą„®.ą„Øą„¦Ā ą¤•ą¤°ą„‹ą¤”
-ą„Ŗą„©.ą„Øą„¦Ā ą¤•ą¤°ą„‹ą¤”
-
Net interest expenses
-ą„©ą„Ŗ.ą„¬ą„¦Ā ą¤•ą¤°ą„‹ą¤”
-ą„©ą„Ø.ą„§ą„¦Ā ą¤•ą¤°ą„‹ą¤”
-ą„Øą„®.ą„Ŗą„¦Ā ą¤•ą¤°ą„‹ą¤”
-
Depreciation and amortization charges
-
-
-
-
EBITDA
ą„«.ą„§ą„ØĀ ą¤…ą¤°ą¤¬
ą„Ŗ.ą„Æą„§Ā ą¤…ą¤°ą¤¬
ą„Ŗ.ą„«ą„ŖĀ ą¤…ą¤°ą¤¬
ą„©.ą„Æą„¬Ā ą¤…ą¤°ą¤¬
Gain or loss from assets sale
-ą„­ą„¦.ą„¦ą„¦Ā ą¤²ą¤¾ą¤–
-ą„Æą„¦.ą„¦ą„¦Ā ą¤²ą¤¾ą¤–
-
-ą„©.ą„Ŗą„¦Ā ą¤•ą¤°ą„‹ą¤”
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer